Roche's Daniel O'Dea will become Gilead's chief executive

, the current chief executive of Roche Pharmaceuticals, will become chief executive from March 1 next year, the company announced.replaces current chief executive John Milligan, who will resign at the end of 2018.Daniel has been head of Roche's pharmaceutical division since 2012 and previously served as head of the company's diagnostics division before joining the company in 1987.Commenting on the appointment,Gilead chairman John Martin said O'Dea was uniquely qualified to play a role in driving innovation in all aspects of the business, given his track record of success in high-tech and competitive treatments, a deep understanding of the changing healthcare environment around the world and a strong commitment.said Gregg Alton, who is currently chief patient officer, would take over as interim chief executive in early 2019 until O'Dea took over.commenting on O'Dea's departure, Severin Schwan, Chief Executive Officer of Roche, said, "He has had an outstanding 31-year career at Roche and has played a key role in bringing a wealth of innovative new drugs to patients." " (Compiled by this web)